Intrathecal hydroxyproyl-beta-cyclodextrin appears to slow progression of cognitive and speech deficits. Hearing loss was a notable adverse event but was ‘manageable’ in this devastating disease, say investigators.
Medscape Medical News
This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.